Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report

Brian J. So, Tanios Bekaii-Saab, Mark A. Bloomston, Tushar Patel

Research output: Contribution to journalArticle

44 Scopus citations

Abstract

Hepatocellular carcinoma is rare, but increasing in prevalence in the United States. Recent studies have shown that sorafenib, a multikinase inhibitor, can reduce tumor progression in patients with this cancer. However, complete remission has not been observed. We report a case of a 78-year old patient with unresectable metastatic hepatocellular carcinoma who had a rapid and complete clinical response following therapy with sorafenib for six months. No evidence of disease recurrence has been noted for 6 months after discontinuation of therapy.

Original languageEnglish (US)
Article number18
JournalJournal of Hematology and Oncology
Volume1
Issue number1
DOIs
StatePublished - Dec 1 2008

ASJC Scopus subject areas

  • Molecular Biology
  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report'. Together they form a unique fingerprint.

  • Cite this